Objection-Thrombin upregulates expression of several proteins in vascular smooth muscle cells (VSMCs) which may contribute to atherosclerosis. Here, we investigated the mechanisms underlying thrombin-induced EGF receptor (EGFR) expression and its effect on VSMCs. Methods and Results-Normal rat VSMCs were used. First, Western blotting and RT-PCR analyses showed that thrombin induces the expression of EGFR at transcription and translation levels in VSMCs. Second, pharmacological inhibitors, dominant negative mutants, and short hairpin RNA interference (shRNA) technology enabled us to demonstrate that thrombin-induced EGFR expression is mediated through PKC(␦)/c-Src-dependent transactivation of EGFR linking to PI3K/Akt and ERK1/2. We further investigated whether the transcription factors AP-1 and NF-B are involved in this response by a promoter assay. Finally, data obtained by using EGFR shRNA technology and XTT assay demonstrated that thrombin-enhanced VSMC proliferation was mediated through upregulation of EGFR.
A ctivation of epidermal growth factor receptor (EGFR) triggers signaling cascades leading to cell proliferation, target gene expression, and neoplastic growth. [1] [2] [3] Overexpression and aberrant activation of the EGFR pathway also trigger proliferation, migration, invasion, and angiogenesis. 4, 5 Moreover, several studies have demonstrated that EGFR expression is transcriptionally regulated in various cell types, 2,6 via transcription factors, including AP-1, early growth response-1 (Egr-1), and NF-B. [7] [8] [9] Therefore, expression of EGFR may play an important role in the development of vascular pathological responses (ie, atherosclerosis).
Thrombin plays a critical role in inflammatory diseases such as atherosclerosis, 10 which triggers platelet aggregation, increased vascular permeability, granulocyte chemotaxis, and endothelial production of prothrombotic factors. 11, 12 Thrombin is a serine proteinase that activates a G protein-coupled receptors (GPCR), also known as protease-activated receptors (PARs) by proteolytic unmasking of the cryptic tethered ligand present in the extracellular N-terminal domain. 13, 14 The PARs have been identified comprising 4 receptors: PAR-1, PAR-2, PAR-3, and PAR-4. 15, 16 Thrombin activates PAR-1, PAR-3, and PAR-4, whereas PAR-2 is mainly activated by trypsin-like enzymes but not by thrombin. 12, 13 The various effects of thrombin are dependent on the expression of thrombin receptors in many cells. 11 In situ hybridization has demonstrated an increase in thrombin receptor mRNA throughout the period of neointimal and vascular lesion development. 17 Moreover, the levels of thrombin are increased during atherosclerosis. 18 The PAR-1 has been shown to be expressed in smooth muscle cells, 13 which is coupled to COX-2 expression induced by thrombin in various cell types. 19, 20 Therefore, thrombin may activate PARs and lead to gene expression which might be implicated in the vascular inflammatory diseases. However, the mechanisms underlying thrombin-induced EGFR expression in vascular smooth muscle cells (VSMCs) remain unclear.
Thrombin activates PARs, which couple to multiple signaling pathways and regulate diverse cellular functions. PARs can couple to G q and G i . 12, 13 Activation of thrombin/PARs system has been shown to trigger hydrolysis of phosphoinositide (PI) and inhibition of adenylyl cyclase via distinct G proteins in platelet and CCL-39 fibroblasts, including G q -like and G i -like proteins, respectively. 16, 21 Thrombin-stimulated MAPKs activation has been shown to initiate cell proliferation. 22 Moreover, thrombin can activate ERK1/2 through alternative transacti-vation of EGFR, 23 mediated via activation of nonreceptor tyrosine kinases such as Src family or release of heparinbinding EGF-like growth factor (HB-EGF) in various cell types. 24 Our previous report also demonstrates that in human and canine tracheal SMCs, thrombin-mediated MAPK activation is associated with cell proliferation. 25, 26 More recently, we have shown that sphingosine 1-phosphate stimulates ERK1/2 and PI3K/Akt phosphorylation associated with EGFR expression in rat VSMCs. 27 In addition, we have also demonstrated that bradykinin stimulates ERK1/2 activation via transactivation of c-Src and EGFR leading to VSMC proliferation. 28 However, the mechanisms underlying thrombin-induced EGFR expression via transactivation of c-Src/EGFR/PI3K/Akt/ERK1/2 linked to cell proliferation are not completely defined in VSMCs.
In this study, we investigated the effect of thrombin on expression of EGFR in rat primary culture VSMCs. These findings indicated that thrombin induces EGFR expression and cell proliferation mediated through both PTX-sensitive G i and G q protein-coupling PARs, autoregulation of PKC(␦)/c-Src-dependent transactivation of EGFR, PI3K-Akt/-ERK1/2, and AP-1/NF-B pathways in VSMCs.
Methods

Reagents and Antibodies
Reagents and Antibodies used are listed in the supplement materials (available online at http://atvb.ahajournals.org).
Rat VSMC Culture
VSMCs were isolated from Sprague-Dawley rats and cultured as previously described. 31 The cells were plated onto (1 mL/well) 12-well culture plates and (10 mL/dish) 10-cm dishes for Western blotting and RT-PCR analyses, respectively.
Preparation of Cell Extracts and Western Blotting Analysis
The cell lysates were collected, and the protein concentration was determined by the BCA reagents. Samples were analyzed by Western blot as previously described. 31
Flow Cytometric Analysis
VSMCs (1ϫ10 6 cells) were treated with or without thrombin (1 U/mL) at 37°C for 6 hour. After treatment, the cells were washed with PBS and suspended in fresh medium. Subsequently, cells were incubated in staining buffer (PBS containing 2% FBS and 0.1% sodium azide) containing anti-EGFR antibody for 1 hour in ice. After incubation, cells were washed and stained with FITC-conjugated IgG secondary antibody for 30 minutes. After staining, cells were fixed with 2% paraformaldehyde and analyzed using a FACSCalibur equipped with CellQuest software (BD Biosciences).
Total RNA Extraction and RT-PCR Analysis
Total RNA was extracted from VSMCs. 20 The cDNA obtained from 0.5 g total RNA was used as a template for PCR amplification. Oligonucleotide primers were designed based on Genbank entries for rat EGFR 29 and ␤-actin. The following primers were used for amplification reaction: for EGFR, forward primer 5Ј-TGGTG-CCGGGTCTGATGATG-3Ј; reverse primer 5Ј-GCAATGCGGTT-CTGATACTG-3Ј; for ␤-actin, forward primer 5Ј-GAACC-CTAAGGCCAACCGTG-3Ј; reverse primer 5Ј-TGGCATAGAG-GTCTTTACGG-3Ј. The amplification was performed in 30 cycles at 94°C, 30s; 55°C, 30 s; 72°C, 1 minute. PCR fragments were analyzed as previously described. 27 These primer sets specifically recognize only the genes of interest as indicated by amplification of a single band of the expected size (502 bp for EGFR and 514 bp for ␤-actin) and direct sequence analysis of the PCR products.
Plasmids, Transient Transfection, and Reporter Assays
The plasmid encoding dominant negative PKC-␦ mutant (DN-PKC␦), cloned into pCO2, was provided by Dr P. Parker (Cancer Research Center UK, London). The plasmids encoding short hairpin RNA of ERK1 (shRNA ERK1 ), Akt (shRNA Akt ), and EGFR (shRNA EGFR ) were provided by Dr C.P. Tseng (Chang Gung University). All plasmids were prepared and transfected as previously described. 20 The B promoter construct pB-luciferase and the AP-1 promoter construct pAP1-luciferase reporter constructs were transfected into VSMCs using the Lipofectamine reagent. The promoter activity was analyzed as previously described 20 and in the supplemental materials.
Electrophoretic Mobility Shift Assay
DNA-protein binding assays were performed using nuclear extract prepared from thrombin (1 U/mL)-treated VSMCs. Synthetic complementary oligonucleotides were 3Ј-biotinylated (MDBio). The sequences of the oligonucleotides used are: 5Ј-TGTCTTTG-ACTCAGCTTCCTCTCCTGCC-3Ј for the wild-type AP-1 and 5Ј-GCTGCCTGC TGGGGAAAGTAC-3Ј for the wild-type NF-B. The electrophoretic mobility shift assay (EMSA) was analyzed as described in the supplemental materials.
Cell Proliferation Assay
To analyze cell proliferation by an XTT assay kit as previously described 30 and in the supplemental materials.
Analysis of Data
Concentration-effect curves were fitted and EC 50 values were estimated using GraphPad Prism Program (GraphPad). Quantitative data were analyzed using ANOVA followed by Tukey honestly significant difference tests between individual groups. Data were expressed as meanϮSEM. A value of PϽ0.05 was considered significant.
Results
Thrombin Induces EGFR Expression
To determine the effect of thrombin on the EGFR expression, treatment of VSMCs with thrombin (1 U/mL) induced EGFR protein expression in a time-and concentration-dependent manner ( Figure 1A and 1B ). There was no significant change in GAPDH expression. Thrombin-induced EGFR expression was further confirmed by a flow cytometry ( Figure 1C ). To further examine whether thrombin-induced EGFR protein expression occurred at the transcriptional level, as shown in Figure 1D , thrombin time-dependently induced EGFR mRNA expression.
Thrombin Induces EGFR Expression via a PTX-Sensitive GPCR
To determine whether thrombin-induced EGFR expression mediates through a GPCR (G i or G q ) linking to PKC and c-Src, pretreatment with a selective thrombin proteolytic activity inhibitor PPACK inhibited thrombin-induced EGFR protein and mRNA expression (supplemental Figure IA and IB). VSMCs have been shown to express PARs, PAR-1 especially, determined by RT-PCR. 20 Pretreatment with a G i protein inhibitor pertussis toxin (PTX), G i protein antagonist (GPAnt2), or G q protein antagonist (GPAnt2A) attenuated thrombin-induced EGFR expression (supplemental Figure IIA and IIB), indicating that thrombin induces EGFR expression mediated through a GPCR (ie, PAR-1) coupling to a PTX-sensitive G i protein and G q protein in VSMCs.
Phospholipases, PKC(␦), and c-Src Mediate Thrombin-Induced EGFR Expression
To investigate whether thrombin-induced EGFR expression is mediated through the activation of phosphatidylcholine (PC)-PLC or PI-PLC, pretreatment with the selective inhibitors of PC-PLC (D609) and PI-PLC (U73122) attenuated thrombin-induced EGFR expression (supplemental Figure  IIIA) , implying the involvement of the PC-PLC and PI-PLC in these responses. Activation of these 2 enzymes increases the generation of diacylglycerol and then activates PKC. To test whether PKC activation is involved in thrombin-induced EGFR expression, a PKC activator PMA (downregulation of PKC in a long-term pretreatment) was used. Pretreatment with PMA for 24 hours reduced thrombin-induced EGFR expression (supplemental Figure IIIB) . PKC isoforms such as ␣, ␤, ␦, and have been shown to express in various cell types. 30, 31 PKC-␦ is the most abundantly expressed in rat VSMCs. 32 Thus, a pan-PKC inhibitor GF109203X and a selective PKC-␦ inhibitor rottlerin were used. Pretreatment with GF109203X or rottlerin attenuated thrombin-induced EGFR expression ( Figure 2A ), suggesting that PKCs, PKC-␦ especially, play a potential role in thrombin-induced EGFR expression. To further ensure the role of PKC-␦, transfection of cells with a dominant negative mutant of PKC-␦ (DN-PKC␦) attenuated thrombin-induced EGFR expression ( Figure 2B) . To examine whether c-Src is involved in these responses, thrombin-induced EGFR expression was blocked by pretreatment with PP1 ( Figure 2C ). Moreover, pretreatment with GF109203X, rottlerin, or PP1 also inhibited thrombin-induced EGFR mRNA expression ( Figure 2D ). These data indicate that PKC(␦) and c-Src are required for thrombin-induced EGFR expression in VSMCs.
Involvement of ERK1/2 Phosphorylation in Thrombin-Induced EGFR Expression
To determine whether thrombin-induced EGFR expression is mediated through ERK1/2-dependent pathway, pretreatment of VSMCs with a selective MEK1/2 inhibitor U0126 attenuated EGFR protein and mRNA expression ( Figure 3A and 3B). To determine whether thrombin-induced EGFR expression is mediated through phosphorylation of ERK1/2, activation of these kinases was assayed by Western blot. As shown in Figure 3C , pretreatment with U0126 decreased thrombinstimulated ERK1/2 phosphorylation. To further confirm ERK1/2 is involved in thrombin-induced EGFR expression, transfection of VSMCs with an ERK1 shRNA (shRNA ERK1 ) downregulated total ERK1 protein expression and attenuated thrombin-induced EGFR expression ( Figure 3D) . These results suggested a link between activation of MEK1/2-ERK1/2 and EGFR expression in VSMCs.
Thrombin-Induced EGFR Expression Mediated Through Transactivation of EGFR
To determine whether thrombin induces EGFR expression via transactivation of EGFR, pretreatment of VSMCs with a selective EGFR inhibitor AG1478 concentration-dependently attenuated thrombin-induced EGFR protein and mRNA expression ( Figure 4A and 4B) . The involvement of EGFR in thrombin-induced responses was further confirmed by that thrombin stimulated phosphorylation of EGFR at Tyr 1173 and Tyr 1068 which was attenuated by pretreatment with AG1478. 20 These results suggested that thrombin-induced EGFR expression is mediated through transactivation of EGFR in VSMCs.
Phosphoinositide-3 kinase (PI3K)/Akt cascade has been shown to be a downstream signal of EGFR activation. To determine whether PI3K/Akt is involved in these responses, pretreatment with a PI3K inhibitor LY294002 blocked thrombin-induced EGFR protein and mRNA expression (supplemental Figure IV and inset panel), suggesting that PI3K is involved in thrombin-induced EGFR expression. We further showed that thrombin stimulated phosphorylation of Akt, a downstream component of PI3K, in a time-dependent manner ( Figure 4C ), which was inhibited by pretreatment with LY294002 ( Figure 4D ), suggesting that PI3K/Akt is involved in these responses. To further ensure that Akt is involved in thrombin-induced EGFR expression, transfection of VSMCs with an Akt shRNA (shRNA Akt ) downregulated total Akt protein expression and attenuated thrombin-induced EGFR expression ( Figure 4E ). These results indicated that activation of PI3K/Akt by thrombin mediates EGFR expression in VSMCs.
Activation of PKC-␦, c-Src, EGFR, PI3K/Akt and ERK was necessary for thrombin-induced EGFR expression in these cells. Signaling through ERK1/2 in response to various GPCR agonists may be mediated through transac- tivation of the EGFR. 23 Therefore, it would be important to differentiate whether PKC(␦) and c-Src are associated with EGFR transactivation leading to ERK1/2 activation. To examine this possibility, the phospho-EGFR was assessed after thrombin stimulation in the presence of inhibitors for c-Src and PKC(␦). First, pretreatment with the inhibitors of c-Src (PP1), pan-PKC (GF109203X), or PKC-␦ (rottlerin) attenuated thrombin-stimulated EGFR phosphorylation (supplemental Figure VA) , suggesting c-Src and PKC-␦ are the upstream components in thrombin-transactivated EGFR. Next, to investigate whether transactivation of EGFR by thrombin is required for ERK1/2 and Akt phosphorylation, pretreatment with AG1478 attenuated thrombin-stimulated ERK1/2 and Akt phosphorylation (supplemental Figure VB) . Moreover, thrombin-stimulated ERK1/2 or Akt phosphorylation was partially inhibited by pretreatment with LY294002 or U0126, respectively (supplemental Figure VC) . Pretreatment with SH-5, an Akt inhibitor, had only a slight decrease in thrombinstimulated ERK1/2 phosphorylation (supplemental Figure  VC) . These results indicated that thrombin-induced EGFR expression was mediated through activation of PKC(␦)/ c-Src, EGFR, PI3K/Akt, and ERK1/2 in VSMCs.
Thrombin Induces EGFR Expression via AP-1 and NF-B
To investigate whether AP-1 and NF-B are involved in thrombin-induced EGFR expression, pretreatment with selective inhibitor of AP-1 (curcumin) or NF-B (helenalin) attenuated thrombin-induced EGFR protein expression (supplemental Figure VIA and VIB) . Thrombin-induced EGFR expression was also inhibited by pretreatment with another AP-1 inhibitor tanshinone IIA (10 mol/L) and NF-B inhibitor Bay11-7082 (1 mol/L; Figure 5A ), indicating that AP-1 and NF-B are required for thrombin-induced EGFR expression. To examine whether thrombin stimulates AP-1 and NF-B DNA binding activities and transcriptional activation, the EMSA and promoter reporter analyses were performed. The data showed that thrombin stimulated AP-1 and NF-B DNA binding activities within 30 to 60 minutes and 15 minutes, respectively ( Figure 5B ). Next, VSMCs were transfected with a promoter construct containing AP-1 or NF-B binding site. These results showed that thrombin-enhanced AP1-luciferase activity was attenuated by pretreatment with AG1478, LY294002, or tanshinone IIA (Figure 5C ). Thrombin-enhanced NF-B-luciferase activity was also inhibited by pretreatment with AG1478, LY294002, or Bay11-7082 ( Figure 5C ). Moreover, transfection with EGFR shRNA significantly blocked thrombin-induced AP-1 and NF-B transcription activities, respectively. For mRNA level, pretreatment with tanshinone IIA or Bay11-7082 also attenuated thrombininduced EGFR mRNA expression ( Figure 5D ). These data indicated that both AP-1 and NF-B are crucial transcription factors for thrombin-induced EGFR expression in VSMCs.
Upregulation of EGFR by Thrombin Enhances Cell Proliferation
To investigate the functional response of thrombin-induced EGFR expression, thrombin time-dependently induced VSMC proliferation detected by an XTT assay ( Figure 6A ). To further demonstrate whether thrombin-induced EGFR expression initiates cell proliferation, VSMCs were transfected with EGFR shRNA (shRNA EGFR ), incubated with or without thrombin, EGF, or in combination. Transfection with EGFR shRNA downregulated the total EGFR protein expression ( Figure 6B , inset panel) and attenuated thrombin-and EGF-induced cell proliferation ( Figure 6B ). These results suggested that upregulation of EGFR by thrombin contributes to cell proliferation of VSMCs.
Discussion
The role of VSMCs has been highlighted in the initiation and progression of atherosclerosis. The proliferation of VSMCs is a fundamental index of vascular injury such as atherosclero- sis. [33] [34] [35] Several studies have shown that EGFR exerts a wide range of biological activities, including proliferation and inflammation. 1, 36 High levels of EGFR have been detected in various dsieases. [37] [38] [39] Moreover, thrombin is elevated in the region during vascular injuries and inflammation. 33 However, little is known about whether EGFR expression induced by thrombin associated with cell proliferation in VSMCs. In this study, our results demonstrated that in VSMCs, thrombin-induced EGFR expression is mediated through a PKC(␦)/c-Srcdependent transactivation of EGFR, PI3K-Akt, and ERK, and AP-1/NF-B pathway. Upregulation of EGFR by thrombin exerted as a phenotype modulation in cell proliferation of VSMCs ( Figure 6C ).
Several studies have reported that thrombin-induced diverse biological effects are mediated through activation of GPCR (PARs) family. 13 Activation of PAR-1 by thrombin initiates multiple signaling pathways which regulate diverse cellular functions. [12] [13] [14] 16 In our study, thrombin-induced EGFR expression was mediated through its proteolytic activity, which was coupled to Gq or Gi protein in VSMCs, consistent with our previous studies from human and canine tracheal SMCs or rat VSMCs. 20, 25, 26 Moreover, other reports 40, 41 and our results have suggested that thrombin-induced phosphorylation of c-Src might be directly mediated through G i protein ␤␥ complex, but concurrently G q protein-mediated phosphorylation of c-Src indirectly mediated through PLC-dependent PKC(␦) activation in VSMCs.
Involvement of c-Src in the transactivation of EGFR by GPCRs has been reported in various cell types. 40, 42 Moreover, PKC may act as an upstream signaling molecule of the EGFR transactivation. 24, 42 Previous studies have shown that PKC-␦ is the most abundantly expressed on rat VSMCs. 30 -32 In this study, we demonstrated that c-Src and PKC␦ are involved in thrombininduced responses which were attenuated by pretreatment with the inhibitors of c-Src and PKC, consistent with our report indicating that thrombin stimulates transactivation of EGFR and ERK1/2 activation via a PKC(␦)/c-Srcdependent manner. 20 Moreover, our results also demonstrated that the PKC(␦)/c-Srcdependent EGFR transactivation was involved in thrombininduced EGFR expression, suggesting that the PKC(␦)/c-Src-dependent transactivation of EGFR is essential for thrombin-induced EGFR expression in VSMCs. These results are consistent with previous studies showing that PKC(␦)/c-Srcdependent transactivation of EGFR was involved in thrombininduced COX-2 expression in VSMCs 20 and LPA-induced IL-8 secretion in HBEpCs, respectively. 43 Moreover, we have demonstrated that thrombin stimulates phosphorylation of PKC-␦ via a G q protein-coupled receptor, but not G i in VSMCs. 20 The role of PKC-␦ in induction of EGFR protein was further confirmed by the results showing that transfection with a DN-PKC␦ significantly attenuated EGFR expression, consistent with a report indicating that thrombin induces COX-2 expression via activation of PKC-␦ in VSMCs. 20 Moreover, thrombin, an agonist of GPCR/PAR, has been found to transactivate EGFR in various cell types such as SMCs, 20, 24 and sequential linking to ERK1/2 activation. 20, 23 Although EGFR transactivation by GPCR agonists has been well studied, little is known about the signaling mechanisms by which thrombin stimulated these events in VSMCs. Our data showed that thrombin-induced EGFR expression was mediated through activation of EGFR and its downstream components including PI3K/Akt and MEK/ERK, which were attenuated by pretreatment with PP1, AG1478, LY294002, and U0126. Moreover, we found that there was a cross-talk between PI3K/Akt and MEK/ERK pathways in these responses, because activation of Akt and ERK1/2 by thrombin was attenuated by pretreatment with either LY294002 or U0126. These results were consistent with previous reports indicating that in VSMCs, transactivation of EGFR leads to cell proliferation 28 and COX-2 expression 20 through PI3Kdependent ERK1/2 activation. The interaction between PI3K/ Akt and ERK1/2 is an important issue to be approached in the future. In contrast, many studies suggest that thrombininduced mitogenic action in astrocytes or VSMCs is independent on EGFR transactivation. 44 These differences may be attributable to cell type specific or different experimental conditions. Furthermore, the inflammatory responses after exposure to extracellular stimuli are highly dependent on activation of AP-1 and NF-B transcription factors in regulation of several gene expression. 45 The 5Ј-flanking region of the EGFR promoter has been shown to contain several binding sequences for various transcription factors including AP-1 and NF-B. 7,9 Activation of AP-1 and NF-B may be involved in EGFR expression in the development of vascular diseases. Herein our data showed that AP-1 and NF-B are involved in thrombin-induced EGFR expression which was abolished by the inhibitors of AP-1 and NF-B. The involvement of AP-1 and NF-B in thrombininduced EGFR expression was further supported by promoter AP1-Luc or B-Luc transcriptional activity assay, which was attenuated by AG1478 or transfection with EGFR shRNA. These findings suggested that thrombin-induced EGFR expression is mediated through AP-1 and NF-B-dependent mechanisms via PKC(␦)/c-Src/EGFR, PI3K/Akt, and ERK1/2 cascades, consistent with our recent studies indicating that S1P mediates EGFR expression 27 and thrombin induces COX-2 expression 20 in VSMCs, which share the same signaling mechanisms. The involvement of NF-B and AP-1 in thrombininduced EGFR expression and cell proliferation is also consistent with previous study indicating that both these transcription factors regulate expression of target genes involved in various injury processes. 46 However, several studies have reported that transactivation, not expression, of EGFR is essential for angiotensin II-and insulin-dependent cellular signaling pathways. In this study, we showed that the EGFR phosphorylation-dependent EGFR overexpression was especially induced by thrombin in VSMCs. Therefore, EGFR phosphorylation-induced EGFR overexpression is still controversial and needs to be further investigated.
In conclusion, we reported that thrombin/PARs system exerted its inducing effects on EGFR gene expression and cell proliferation in rat cultured VSMCs ( Figure 6C ). The G q protein and PTX-sensitive G i protein-coupled PAR-1, PKC(␦), c-Src, EGFR, PI3K/Akt, ERK, AP-1, and NF-B cascades cooperatively mediated these effects of thrombin. These findings concerning thrombin-induced EGFR expression and cell proliferation imply that thrombin might play an important role in vascular diseases like atherosclerosis, mediated through PKC(␦)/c-Srcdependent transactivation of EGFR, PI3K-Akt and ERK, AP-1 and NF-B signaling pathways in rat VSMCs. The role of VSMCs, in addition to their contractile function, as inflammatory cells involved in the production of inflammatory mediators and cell proliferation may contribute to the vascular inflammation in atherosclerosis.
